The Predicting Effect of ASXL1 Mutation on BCR-ABL Transcript Types and Responses to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Abstract

Objective: In order to support clinical management, we sought to show how ASXL1 mutations affect prognosis as a bio-marker for various management responses and illness progress. 

Study Design: Cross-sectional study 
Place and Duration of Study: This study was conducted at the Al Diwaniyah Teaching Hospital and the Department of Pharmacology & Therapeutics, College of Medicine, University of Al-Qadisiyah, Iraq from 1st July 2024 to 31st January 2025. 

Methods: A total of 51 patients with CML were enrolled. DNA was extracted from all patients for amplification of theASXL1 gene using specific primers and detection of the 1934 (c.1934dupG) mutation by sequencing. 

Result: Only 2 were found to have this type of mutation, as revealed by sequencing of the amplified gene.

Conclusion: ASXL1 mutations might be promising prognostic bio-markers to regulate each patient's finest TKIs and avoid CML progression.